Literature DB >> 23716859

Nasal involvement in hand and foot syndrome.

Anil Mishra1, Prashanna R Shrestha, R V Ramanna Rao, Ajay Kumar.   

Abstract

Entities:  

Year:  2013        PMID: 23716859      PMCID: PMC3657269          DOI: 10.4103/0019-5154.108114

Source DB:  PubMed          Journal:  Indian J Dermatol        ISSN: 0019-5154            Impact factor:   1.494


× No keyword cloud information.
Sir, Hand and Foot Syndrome, otherwise termed as palmar-plantar erythrodysesthesia (PPE), is a side effect of some of the chemo therapeutic agents and biologics. It is a dose related toxicity. Clinically it presents as varying degree of paraesthesia and erythema over palms and soles which later turns into hyperpigmentation and sometimes scaling with exfoliations. We report here a case of hand and foot syndrome due to capecitabine. The peculiarity of our case is the involvement of nose and sparing of soles. A 62-year-old male patient diagnosed as peri ampullary carcinoma was admitted to our private ward. He had undergone Whipple's operation for the same and was on chemotherapy (Capecitabine) for widespread metastasis. The patient was referred to us with complains of hyperpigmentation over nose, hand and few areas of foot preceeded by pain in these areas. After a detailed history taking and examination, it was found that the patient had received two cycles of Capecitabine. After the first two cycles, there was no cutaneous complains. While receiving the third cycle, he developed pain and subsequent hyperpigmentation over nose [Figure 1]. Within a few days, he developed similar hyperpigmentation over hand [Figure 2] and parts of dorsum of foot. After a few days, he developed exfoliations from some of the areas of palm [Figure 3]. The patient was diagnosed as a case of hand and foot syndrome.
Figure 1

Hyperpigmentation over nose

Figure 2

Hyperpigmentation over both palms

Figure 3

Exfoliation over the finger tips

Hyperpigmentation over nose Hyperpigmentation over both palms Exfoliation over the finger tips The dose of capecitabine was advised to be reduced and pyridoxine tablet was administered along with topical steroid. There was some improvement after a few weeks. However the patient succumbed to the widespread metastasis within a month. PPE is a distinctive and relatively frequent toxic reaction related to some chemotherapeutic agents.[1] Drugs that have been associated include 5-flurouracil, capecitabine, cytarabine, doxorubicin, epirubicin, high-dose interleukin-2, fluorodeoxyuridine (FUDR), hydroxyurea, mercaptopurine, cyclophosphamide, and docetaxel.[2] PPE seems to be dose dependent and both peak drug concentration and total cumulative dose determine its occurrence.[1] The cause of PPE is currently unknown. The most likely and accepted hypothesis is a direct toxic effect of the chemotherapeutic drug against epidermal cells because of the dose-relationship and the common histopathologic findings with other entities produced by direct toxicity. There is no clear explanation for its particular distribution. Specific features of the hands and feet could play a role in its location. The thick stratum corneum, the temperature gradient, the vascular anatomy, the rapidly dividing epidermis, the absence of sebaceous glands and hairs follicles, the high concentration of eccrine glands, and wide dermal papillae may all be important in the pathogenesis.[1] The distribution of eccrine sweat glands in our body, according to decreasing density, is palms and sole > head > trunk > extremities.[3] Considering this in mind we can explain the occurrence of lesion also over nose in our case. Clinically it presents as symmetrical dysesthesias followed by burning pain, erythema, and swelling in the hands and feet, which may be severe enough to limit activity. Blisters and desquamation are followed by extensive superficial exfoliation.[4] The hands are usually more severely affected than the feet, and may be the only area involved, as described in our case where the sole was spared. Rarely, erythema may also be noted outside the palmar and plantar regions.[1] Clinically Hand and Foot Syndrome is graded as follows:[5] Grade 1 No symptoms or only slight dysaesthesia, with mild redness Grade 2 Dysaesthesia but no pain, severe redness and/or swelling Grade 3 Dysaesthesia with pain, severe redness and/or swelling Grade 4 Pain and impaired function in the activities of daily living, desquamation, blistering and ulceration Although the diagnosis is usually evident, it may be difficult to differentiate hand and foot syndrome from acute graft versus host disease. The involvement of the palms and soles in AGVHD is usually a diffuse macular erythema which may form papules, in contrast to the areas of well-defined intense erythema and edema that are seen in PPE.[6] Histologically it presents as interface dermatitis with a cell-poor infiltrate and a variable degree of epidermal necrosis.[7] As regards to treatment, there is no satisfactory medication for this entity. Dose reduction or withdrawal of the offending drug is effective. Symptomatic relief may be obtained with wound care to prevent infection, elevation to reduce edema, cold compresses, and pain medications.[89] Potent topical corticosteroids with or without emollients have proven to be of some efficacy, so also systemic corticosteroids. Pyridoxine (vitamin B6) seems to be the most useful treatment. It helps to alleviate the pain and, consistently allows the dose of chemotherapy to be maintained.[1] We report this case because of two peculiarities- involvement of nose and sparing of soles.
  8 in total

Review 1.  Chemotherapy-induced acral erythema.

Authors:  B R Baack; W H Burgdorf
Journal:  J Am Acad Dermatol       Date:  1991-03       Impact factor: 11.527

Review 2.  The cutaneous histopathology of chemotherapeutic reactions.

Authors:  J E Fitzpatrick
Journal:  J Cutan Pathol       Date:  1993-02       Impact factor: 1.587

3.  Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells.

Authors:  R Valks; J Fraga; J Porras-Luque; A Figuera; A Garcia-Diéz; J Fernändez-Herrera
Journal:  Arch Dermatol       Date:  1997-07

Review 4.  Mucocutaneous reactions to chemotherapy.

Authors:  W S Susser; D L Whitaker-Worth; J M Grant-Kels
Journal:  J Am Acad Dermatol       Date:  1999-03       Impact factor: 11.527

Review 5.  Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management.

Authors:  E Nagore; A Insa; O Sanmartín
Journal:  Am J Clin Dermatol       Date:  2000 Jul-Aug       Impact factor: 7.403

6.  Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.

Authors:  Roger von Moos; Beat J K Thuerlimann; Matti Aapro; Daniel Rayson; Karen Harrold; Jalid Sehouli; Florian Scotte; Domenica Lorusso; Reinhard Dummer; Mario E Lacouture; Jürgen Lademann; Axel Hauschild
Journal:  Eur J Cancer       Date:  2008-03-10       Impact factor: 9.162

7.  Penile involvement with hand-foot syndrome.

Authors:  Steven M Sorscher
Journal:  Am J Clin Dermatol       Date:  2004       Impact factor: 7.403

8.  Hand-foot syndrome due to capecitabine.

Authors:  Amar Surjushe; Resham Vasani; Sudhir Medhekar; Minal Thakre; D G Saple
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.